Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 6Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms 1Lymphoma 1Liposarcoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Radiotherapy 5Gemcitabine 4Cyclophosphamide 4pazopanib 3Docetaxel 3Biopsy 3pembrolizumab 2olaparib 2liposomal doxorubicin 2Vincristine 2Trastuzumab 2Trabectedin 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Proton Therapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Filgrastim 2Etoposide 2Drug Therapy 2Doxorubicin 2Celecoxib 2Carboplatin 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trastuzumab biosimilar HLX02 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma × ixazomib × Clear all
NCT03880123 2020-11-27

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Columbia University

Phase 1 Withdrawn
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡